2026 Portfolio Update

Looking for 300% average peak gain in 2026

Aduro Clean Technologies (Nasdaq: ADUR | CAD: ACT)
Released Q2 FY2026 results today showing 222% revenue growth (although most would consider it pre-revenue at these levels), with the Next Generation Pilot Plant commissioning advancing and a global site-selection process underway for their Demonstration Plant. They also just closed a US$20M public offering to fund the Demo Plant and graduated from the Shell GameChanger program. Volume has been wild, the price has been volatile and trending up with a lot of traders eyeing the $22-23 level, which is about a 50% gain from here. I remain biased, Aduro is my baby and I continue to add.

Rocket Doctor AI (USOTC: AIRDF | CAD: AIDR)
Completed the Alea Health acquisition, adding therapist-led mental health capabilities to their AI-powered platform. They now have access to 13M+ insured members across Medicare, Medicaid, VA, and Commercial contracts in California, New York, and Maryland. With a $3M private placement underway and a fresh analyst report out of Maxim giving them a $2.16 USD price target in 12-months (current price is ~57 cents USD). She remains a top pick for me…

CISO Global (CISO)
CISO is sitting about where it was when I originally introduced it (~50 cents) after running to a high of $1.70 last year. After a very disappointing Q3, with underhelming SaaS numbers, CISO’s pivot to software is now gaining traction with over $1.1M in CHECKLIGHT software sales booked. The two big things that I am watching for are continued SaaS growth and to see if they can pull off a transformative transaction. This remains a volatile and high-risk play, but I think we have already reached maximum downside when you take into account their active revenue and margins. They are trading at a ridiculously low multiple for the sector. They are currently under a Nasdaq non-compliance notice for trading under $1.00 with until June 29 to remedy, I would expect that they would get a 180 day extension beyond that if needed.

South Pacific Metals (US OTC: SPMEF | CAD: SPMC)
Drilling boots are on the ground. Commenced their maiden drilling program at Ontenu Northeast in Papua New Guinea with shockingly good surface results including 21.2% Cu and 310 g/t Ag. They bookend K92’s multibillion-dollar gold mine and just raised 9.2m CAD. I am frustrated by how much the market is sleeping on this one, but I am happy with the amount of time I’ve had to build my position.

Medicenna (US OTC: MDNAF | CAD: MDNA) long update
Medicenna released their 2026 outlook yesterday morning and I want to highlight something important: MDNA11 doesn’t need Keytruda to work.

The headline numbers, 50% objective response rate in expansion cohorts, 42% in patients who already failed checkpoint inhibitors, those are monotherapy results. No Keytruda. No Opdivo. Just MDNA11 alone.

Think about that. These are patients who tried the blockbuster immunotherapies and they stopped working. MDNA11 is rescuing responses where checkpoints have failed. That’s a big deal.

Why this matters for the investment thesis: There are now multiple paths to value here.

1. Monotherapy salvage: Patient fails Keytruda, give MDNA11 alone. This is the registrational path they’re planning for melanoma.

2. Combination play Pair MDNA11 with Keytruda upfront to expand the responder population from ~30% to potentially 40-50%.

3. Neoadjuvant (NEO-CYT) MDNA11 + checkpoint before surgery in earlier-stage melanoma.

The combination story makes Medicenna attractive to Merck as a Keytruda extender. But the monotherapy data? That’s arguably more valuable from an M&A perspective, it means MDNA11 has standalone utility, not just as a sidekick. Broader market, more strategic flexibility for any acquirer.

Don’t forget that they only have enough runway to get them into Q3. I honestly don’t understand why the price is as low as it is, I’m beginning to feel a bit crazy when it comes to Medicenna.

Charbone Hydrogen (US OTC: CHHYF | CAD: CH)
Just secured their first US order for clean ultra-high purity hydrogen from a customer affiliated with a major Japanese conglomerate in New York State. This is a pivotal commercial breakthrough that validates their value proposition and opens the door to America’s Tech Valley. I have made a lot of money here and it is a trade that I will be entering and exiting based only on price action.

2026 Portfolio Additions

LibertyStream ( US OTC: VLTLF | CAD: LIB)
Liberty Stream went from a swing trade back in October to a full portfolio position for me. It is the first 4x of the year for me and itis looking like it could run a lot farther. They’ve processed 350,000+ barrels of brine at 99% lithium extraction and are setting a shareholder vote March 31 to re-domicile to Texas as they target commercial operations in late 2026.

Panthera Resources (US OTC: PATRF | LSE: PAT)
The $1.58B India arbitration case is well-advanced with the big hearing scheduled for December 2026. It is still sitting at about 30 cents US equivalent to abot 5% of the claim amount. This one has been tough to get on the US side, as there are not a lot of shares available on our side of the water, and I don’t think people should be chasing this. For now, there is a window at open everyday in the US where it is still trading in the UK and shares are available. These shares don’t typically show on the US volume at the end of the day, but it is trading here

GOAT Industries (US OTC : BGTTF | CAD: GOAT)
If you took me up on the offer, you got into the GOAT private placement at 30 cents Canadian with a warrant 45 cents. Right now it is sitting at 57 cents CAD. They just uplisted to the OTCQB in the US as BGTTF. I took a large position in the placement and I will be doing a full piece on this investment and why I chose it. In short, GOAT invests in other companies that they think have potential. Sort of like an incubator, I am a big fan of these because I find them to be the most accessible form of venture capital for regular people like us. They recently picked up BetSource, which is an online betting platform. I am going to keep it simple for the purpose of this update, but I was very much impressed by their technology and the growth of that market. More on GOAT later, but let me know if you want me to forward private placement info to you (I don’t make any money off of you buying and I only send ones that I am participating in).

GoGo AI Network (US OTC: GOGAF | CAD: Gogo) I just picked this one back up, back in 2024 I held it for a while when it was MedBright AI. It has morphed into a VC type AI and Robotics play. I like the price point, the new president and stake in Algo8 (industrial ai). I will be doing a full deep dive into the company coming soon, but if you are interested, understand that the float is tightly held so I wouldn’t buy aggressively or the price could get away from you.

Thank you for all the suggestions everyone sent. I am still diligently researching all of them. I am hoping to add a low price/higher risk play, another clean tech company and another commodities play.

Disclaimer

As always, this is not investment advice and I am not an investment advisor. Investing is risky, protect your capital. Investing is risky and the investments I like are in the high risk zone. XO, Penny

Arelated party owns 45 Degrees.

45 Degrees, Inc (”We” or “Us”) are not securities dealers or brokers, investment advisers or financial advisers, and you should not rely on the information herein as investment advice. Rocket Doctor AI entered into a contract for $180,000 and 400,000 options at 45 cents Canadian, to provide marketing services for a term of 6 months. We or certain non-arms length parties own shares of Rocket Doctor AI. This article is informational only and is solely for use by prospective investors in determining whether to seek additional information. This does not constitute an offer to sell or a solicitation of an offer to buy any securities. Examples that we provide of share price increases pertaining to a particular Issuer from one referenced date to another represent an arbitrarily chosen time period and are no indication whatsoever of future stock prices for that Issuer and are of no predictive value. Our stock profiles are intended to highlight certain companies for your further investigation; they are not stock recommendations or constitute an offer or sale of the referenced securities. The securities issued by the companies we profile should be considered high risk; if you do invest despite these warnings, you may lose your entire investment. Please do your own research before investing, including reading the companies’ SEDAR+ and SEC filings, press releases, and risk disclosures.